MYCN and neuroblastoma: However abnormalities in multiple p53 pathway members emerge after pharmacological treatment, correlating with therapeutic resistance and reinforcing the notion that strong selective pressure for p53 inactivation exists in MYCN-driven neuroblastoma [28], [29].